Predictors of day-100 transplant-related mortality (TRM) and 3-year survival (univariate analyses)
| Covariates . | No. . | Day-100 TRM . | Log Rank PValue . | 3-Year Survival . | Log-Rank P Value . |
|---|---|---|---|---|---|
| Recipient age at transplant | |||||
| <10 years | 29 | 31% | .17 | 39% | .18 |
| ≥10 years | 44 | 45% | 28% | ||
| Elevated serum transaminases | |||||
| No | 51 | 32% | .03 | 36% | .11 |
| Yes | 15 | 60% | 24% | ||
| Androgens before transplant | |||||
| No | 27 | 30% | .22 | 49% | <.03 |
| Yes | 41 | 47% | 21% | ||
| Transfusions before transplant | |||||
| <20 | 23 | 30% | .40 | 37% | .66 |
| ≥20 | 43 | 42% | 32% | ||
| Severe cytopenia before transplant | |||||
| None, 1 or 2 | 55 | 37% | .23 | 35% | .32 |
| 3 | 12 | 50% | 25% | ||
| Malignancy before transplant | |||||
| No | 58 | 38% | .49 | 35% | .41 |
| Yes | 11 | 46% | 27% | ||
| Pretransplant CMV recipient serology | |||||
| Negative | 41 | 32% | .14 | 39% | .09 |
| Positive | 24 | 51% | 18% | ||
| Donor gender | |||||
| Female | 37 | 46% | .14 | 22% | <.01 |
| Male | 32 | 32% | 48% | ||
| Cyclophosphamide total dose | |||||
| 20 mg/kg | 14 | 36% | .79 | 34% | .82 |
| 40-45 mg/kg | 53 | 42% | 31% | ||
| Irradiation for conditioning | |||||
| TAI | 28 | 39% | .89 | 33% | .77 |
| TBI | 39 | 36% | 35% | ||
| Anti-T serotherapy for conditioning | |||||
| No | 19 | 47% | .51 | 21% | .19 |
| Yes | 50 | 36% | 44% | ||
| T-cell depletion | |||||
| No | 43 | 42% | .61 | 27% | .33 |
| Yes | 26 | 35% | 44% | ||
| Methotrexate for GVHD prophylaxis | |||||
| No | 47 | 45% | .22 | 29% | .08 |
| Yes | 22 | 27% | 44% |
| Covariates . | No. . | Day-100 TRM . | Log Rank PValue . | 3-Year Survival . | Log-Rank P Value . |
|---|---|---|---|---|---|
| Recipient age at transplant | |||||
| <10 years | 29 | 31% | .17 | 39% | .18 |
| ≥10 years | 44 | 45% | 28% | ||
| Elevated serum transaminases | |||||
| No | 51 | 32% | .03 | 36% | .11 |
| Yes | 15 | 60% | 24% | ||
| Androgens before transplant | |||||
| No | 27 | 30% | .22 | 49% | <.03 |
| Yes | 41 | 47% | 21% | ||
| Transfusions before transplant | |||||
| <20 | 23 | 30% | .40 | 37% | .66 |
| ≥20 | 43 | 42% | 32% | ||
| Severe cytopenia before transplant | |||||
| None, 1 or 2 | 55 | 37% | .23 | 35% | .32 |
| 3 | 12 | 50% | 25% | ||
| Malignancy before transplant | |||||
| No | 58 | 38% | .49 | 35% | .41 |
| Yes | 11 | 46% | 27% | ||
| Pretransplant CMV recipient serology | |||||
| Negative | 41 | 32% | .14 | 39% | .09 |
| Positive | 24 | 51% | 18% | ||
| Donor gender | |||||
| Female | 37 | 46% | .14 | 22% | <.01 |
| Male | 32 | 32% | 48% | ||
| Cyclophosphamide total dose | |||||
| 20 mg/kg | 14 | 36% | .79 | 34% | .82 |
| 40-45 mg/kg | 53 | 42% | 31% | ||
| Irradiation for conditioning | |||||
| TAI | 28 | 39% | .89 | 33% | .77 |
| TBI | 39 | 36% | 35% | ||
| Anti-T serotherapy for conditioning | |||||
| No | 19 | 47% | .51 | 21% | .19 |
| Yes | 50 | 36% | 44% | ||
| T-cell depletion | |||||
| No | 43 | 42% | .61 | 27% | .33 |
| Yes | 26 | 35% | 44% | ||
| Methotrexate for GVHD prophylaxis | |||||
| No | 47 | 45% | .22 | 29% | .08 |
| Yes | 22 | 27% | 44% |
CMV indicates cytomegalovirus; TAI, thoracoabdominal irradiation; TBI, total body irradiation; GVHD, graft-versus-host disease.